Prelude Therapeutics revenue was $6.50M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $6.5M, up Infinity% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PRLD annual revenue was $0.0, with N/A growth year-over-year.
PRLD past revenue growth
How has PRLD's revenue growth performed historically?
On Invalid Date, Prelude Therapeutics (NASDAQ: PRLD) reported Q3 2025 revenue of $6.50 million up 116.67% year over year. In the same quarter last year, Prelude Therapeutics's revenue was $3.00 million.
What was Prelude Therapeutics's revenue in 2024?
Prelude Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
How much does Prelude Therapeutics make in a day?
Based on Prelude Therapeutics annual revenue for the past five years, PRLD makes an average of $0.00 per day.
What was Prelude Therapeutics's annual revenue growth in the past year?
As of Q4 2025, Prelude Therapeutics's revenue has grown 116.67% year over year. This is 186.14 percentage points lower than the US Biotechnology industry revenue growth rate of 302.81%. Prelude Therapeutics's revenue in the past year totaled $6.50 million.
How much does Prelude Therapeutics make in a year?
Prelude Therapeutics's revenue by year for the past five years is:
Prelude Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
Prelude Therapeutics's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
Prelude Therapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Prelude Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Prelude Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.